Concepedia

Paul Panorchan

PP

8

Publications

381

Citations

8

H-Index

2012

Active since

Affiliations

Vertex Pharmaceuticals (United States)(Current)

Merck & Co., Inc., Rahway, NJ, USA (United States)

Cornell University

The University of Queensland

Imperial College London

Paul Panorchan is an author at Vertex Pharmaceuticals (United States) specializing in hepatitis, hepatitis c, and hepatology.

Top concepts

Publications per year

2012–2022

8

Publications

8

Ivacaftor in Infants Aged 4 to <12 Months with Cystic Fibrosis and a Gating Mutation. Results of a Two-Part Phase 3 Clinical Trial

Jane C. Davies, Claire Wainwright, Gregory S. Sawicki et al. · American Journal of Respiratory and Critical Care Medicine · 2020 · 94 citations · Full text

Correlation of sweat chloride and percent predicted FEV1 in cystic fibrosis patients treated with ivacaftor

Meredith C. Fidler, Jack Beusmans, Paul Panorchan et al. · Journal of Cystic Fibrosis · 2016 · 79 citations · Full text

A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR mutation and a residual function mutation

Jane C. Davies, Isabelle Sermet‐Gaudelus, Lutz Naehrlich et al. · Journal of Cystic Fibrosis · 2020 · 64 citations

UGT2B17 Genetic Polymorphisms Dramatically Affect the Pharmacokinetics of MK-7246 in Healthy Subjects in a First-in-Human Study

Yuhan Wang, Michele Trucksis, Joshua McElwee et al. · Clinical Pharmacology & Therapeutics · 2012 · 46 citations · Full text

Physiologically Based Pharmacokinetic Modeling of CFTR Modulation in People with Cystic Fibrosis Transitioning from Mono or Dual Regimens to Triple-Combination Elexacaftor/Tezacaftor/Ivacaftor

Alice Tsai, Shu-Pei Wu, Eric L. Haseltine et al. · Pulmonary Therapy · 2020 · 36 citations · Full text

Rows per page

1–5 of 8